Martin Eatock

3.7k total citations · 1 hit paper
45 papers, 1.8k citations indexed

About

Martin Eatock is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Martin Eatock has authored 45 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 8 papers in Surgery. Recurrent topics in Martin Eatock's work include Pancreatic and Hepatic Oncology Research (14 papers), Gastric Cancer Management and Outcomes (14 papers) and Colorectal Cancer Treatments and Studies (12 papers). Martin Eatock is often cited by papers focused on Pancreatic and Hepatic Oncology Research (14 papers), Gastric Cancer Management and Outcomes (14 papers) and Colorectal Cancer Treatments and Studies (12 papers). Martin Eatock collaborates with scholars based in United Kingdom, United States and Spain. Martin Eatock's co-authors include Juan W. Valle, Richard H. Wilson, S.B. Kaye, Andreas G. Schätzlein, David Cunningham, John P. Neoptolemos, David B. Smith, William P. Steward, Stephen Falk and F. Adab and has published in prestigious journals such as Journal of Clinical Oncology, Gut and Clinical Cancer Research.

In The Last Decade

Martin Eatock

44 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer

2009 602 citations David Cunningham, Juan W. Valle et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Martin Eatock

Since Specialization

Citations

This map shows the geographic impact of Martin Eatock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Eatock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Eatock more than expected).

Fields of papers citing papers by Martin Eatock

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Eatock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Eatock. The network helps show where Martin Eatock may publish in the future.

Co-authorship network of co-authors of Martin Eatock

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Eatock. A scholar is included among the top collaborators of Martin Eatock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Eatock. Martin Eatock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Feasibility of delivering supervised exercise training following surgical resection and during adjuvant chemotherapy for pancreatic ductal adenocarcinoma (PRECISE): a case series 2023 ·BMC Sports Science Medicine and Rehabilitation ·Malcolm Brown, Dominic O’Connor, Richard Turkington, Martin Eatock, Rebecca V. Vince, Claire Hulme, (unknown), R.L. Robinson, Jonathan Wadsley, Anthony Maraveyas, Gillian Prue	1
2	Exercise efficacy and prescription during treatment for pancreatic ductal adenocarcinoma: a systematic review 2021 ·BMC Cancer ·Dominic O’Connor, Malcolm Brown, Martin Eatock, Richard Turkington, Gillian Prue	15
3	A phase I study of olaparib in combination with capecitabine-based chemoradiation (CRT) in patients (pts) with locally advanced pancreatic cancer (LAPC). 2020 ·Journal of Clinical Oncology ·T.R. Jeffry Evans, Martin Eatock, Liz-Anne Lewsley, Caroline Kelly, Elaine McCartney, Aileen Duffton, (unknown), Claire Harrison, Colin Purcell, Miranda Ashton, (unknown), (unknown), Anthony J. Chalmers, Fiona Thomson, Chantévy Pou, Alan Bilsland, (unknown), David E. McIntosh, Derek Grose	4
4	Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma 2019 ·European Journal of Cancer ·Anne Thomas, Pradeep S. Virdee, Martin Eatock, Simon Lord, Stephen Falk, Alan Anthoney, Richard Turkington, (unknown), (unknown), Linda Collins, Sharon Love, Joanna Moschandreas, Mark R. Middleton	12
5	A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract 2016 ·BMC Research Notes ·Janet Graham, Kirsty U Boyd, Fareeda Y. Coxon, Lucy Wall, Martin Eatock, Tim Maughan, Martin Highley, (unknown), (unknown), (unknown), T.R. Jeffry Evans	9
6	Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma 2016 ·BMC Cancer ·David Propper, Keith Jones, Alan Anthoney, Wasat Mansoor, Daniel Ford, Martin Eatock, Roshan Agarwal, (unknown), Tomohisa Saito, (unknown), T.R. Jeffry Evans	3
7	GASTRIC ANTRAL VASCULAR ECTASIA: CLINICAL FEATURES, ASSOCIATIONS AND PROGNOSIS 2013 ·Gut ·(unknown), (unknown), (unknown), Colin Purcell, Martin Eatock	1
8	A systematic review of non-surgical treatments for pancreatic neuroendocrine tumours 2013 ·Cancer Treatment Reviews ·Juan W. Valle, Martin Eatock, (unknown), Zahava Gabriel, (unknown), Stephen Mitchell	41
9	The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer 2013 ·Cancer Immunology Immunotherapy ·Nicola Annels, Victoria Shaw, (unknown), Lucinda Billingham, Pippa Corrie, Martin Eatock, Juan W. Valle, David B. Smith, Jonathan Wadsley, David Cunningham, Hardev Pandha, John P. Neoptolemos, Gary Middleton	80
10	A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma 2013 ·Investigational New Drugs ·Richard Turkington, Colin Purcell, (unknown), (unknown), (unknown), David Law, Ryan S. Gallagher, Melanie Morris, Richard H. Wilson, Martin Eatock	6
11	A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors 2011 ·Clinical Cancer Research ·Simon Pacey, Richard H. Wilson, Mike Walton, Martin Eatock, Anthea Hardcastle, (unknown), Hendrik‐Tobias Arkenau, (unknown), Udai Banerji, Belle Roels, (unknown), Wynne Aherne, Johann S. de Bono, Florence I. Raynaud, Paul Workman, Ian Judson	154
12	A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours 2011 ·British Journal of Cancer ·Ruth Plummer, Richard H. Wilson, Hilary Calvert, Alan V. Boddy, Melissa Griffin, J Sludden, Michael J. Tilby, Martin Eatock, D. Graham Pearson, Christopher J. Ottley, Yasuhiro Matsumura, Kazunori Kataoka, Takako Nishiya	303
13	Phase I and pharmacokinetic study of NC-6004, a new platinum entity of cisplatin-conjugated polymer forming micelles 2008 ·Journal of Clinical Oncology ·Richard H. Wilson, (unknown), Jean‐François Adam, Martin Eatock, Alan V. Boddy, Melanie Griffin, C. Ryan Miller, Yasuhiro Matsumura, Takashi Shimizu, Hilary Calvert	26
14	Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma 2006 ·British Journal of Cancer ·Stephen Falk, Alan Anthoney, Martin Eatock, Eric Van Cutsem, (unknown), Hilary Glen, Juan W. Valle, Daniel W. Drolet, Donald G. Albert, D. Ferry, Jaffer A. Ajani	10
15	Phase II study of troxacitabine in chemotherapy-naïve patients with advanced cancer of the pancreas 2005 ·Annals of Oncology ·Réjean Lapointe, (unknown), William P. Steward, Robert E. Hawkins, Gerald Batist, M. Vincent, Renaud Whittom, Martin Eatock, Jacques Jolivet, Malcolm J. Moore	18
16	Capecitabine (Xeloda®) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors 2002 ·Annals of Oncology ·Eduardo Díaz‐Rubio, T.R. Jeffry Evans, Josep Tabernero, J Cassidy, Javier Sastre, Martin Eatock, D. Bisset, (unknown), José Baselga	88
17	True 2000 ·British Journal of Cancer ·Martin Eatock, (unknown), T.R. Jeffry Evans, J. P. Paul, P. M. Wilson, (unknown), (unknown), M Soukop	14
18	Activity of Doxorubicin Covalently Bound to a Novel Human Serum Albumin Microcapsule 1999 ·Investigational New Drugs ·Martin Eatock, (unknown), (unknown), Wilson J. Angerson, Colin S. McArdle, (unknown), Chris Twelves	13
19	Randomized multicentre trial of filgrastim as an adjunct to combination chemotherapy for Hodgkin's disease 1998 ·Clinical Oncology ·DJ Dunlop, Martin Eatock, James Paul, Stewart Anderson, Nicholas S. Reed, M Soukop, N.P. Lucie, (unknown), P Tansey, William P. Steward	14
20	Bioavailability of subcutaneous 5-fluorouracil: a case report 1996 ·Cancer Chemotherapy and Pharmacology ·Martin Eatock, (unknown), David J. Dunlop, M. Soukop, Dave G. Watson	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact